Century Therapeutics, Inc.
NASDAQ:IPSC
1.26 (USD) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.771 | 0.855 | 0.268 | 0.148 | 0.099 | 1.72 | 0.521 | 2.224 | 1.396 | 1.058 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 3.462 | 3.226 | 3.552 | 1.787 | 2.409 | 2.17 | 3.383 | 2.774 | 1.668 | 21.196 | 1.885 | 1.044 | 0.935 | 0.948 | 0 | 0 | 0 | 0 |
| Gross Profit
| -2.691 | -2.371 | -3.284 | -1.639 | -2.31 | -0.45 | -2.862 | -0.55 | -0.272 | -20.138 | -1.885 | -1.044 | -0.935 | -0.948 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| -3.49 | -2.773 | -12.254 | -11.074 | -23.333 | -0.262 | -5.493 | -0.247 | -0.195 | -19.034 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 23.758 | 20.195 | 22.296 | 22.788 | 22.727 | 24.899 | 25.585 | 25.898 | 24.494 | 31.196 | 21.796 | 19.545 | 18.933 | 15.374 | 12.442 | 10.812 | 8.484 | 7.943 |
| General & Administrative Expenses
| 8.306 | 8.743 | 8.589 | 8.986 | 8.229 | 8.902 | 8.242 | 8.064 | 8.253 | 7.298 | 6.177 | 6.282 | 4.088 | 2.688 | 2.816 | 2.319 | 2.31 | 2.05 |
| Selling & Marketing Expenses
| 0.782 | 0 | -3.552 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.088 | 8.743 | 5.037 | 8.986 | 8.229 | 8.902 | 8.242 | 8.064 | 8.253 | 7.298 | 6.177 | 6.282 | 4.088 | 2.688 | 2.816 | 2.319 | 2.31 | 2.05 |
| Other Expenses
| -0.012 | 0.011 | -0.015 | 0.012 | -0.186 | -0.194 | 2.069 | 1.387 | 0 | 10 | 0 | 0 | 0 | 0.028 | 0 | 0 | 0 | 0.32 |
| Operating Expenses
| 32.846 | 28.938 | 27.333 | 31.774 | 30.956 | 33.801 | 33.827 | 33.962 | 32.747 | 38.494 | 27.973 | 25.827 | 23.021 | 18.062 | 15.258 | 13.131 | 10.794 | 9.993 |
| Operating Income
| -35.537 | -31.309 | -30.617 | -35.626 | -35.077 | -32.081 | -33.306 | -31.738 | -31.351 | -37.436 | -27.973 | -25.827 | -23.021 | -18.062 | -15.258 | -13.131 | -15.516 | -9.993 |
| Operating Income Ratio
| -46.092 | -36.619 | -114.243 | -240.716 | -354.313 | -18.652 | -63.927 | -14.271 | -22.458 | -35.384 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.352 | 3.248 | -9.65 | -3.988 | -4.406 | 2.025 | 1.656 | 1.014 | 0.381 | -0.061 | -5.456 | -0.182 | -0.252 | 0.028 | 0.704 | 0.061 | -4.722 | 0.32 |
| Income Before Tax
| -31.185 | -28.061 | -40.267 | -32.128 | -32.341 | -30.056 | -31.65 | -30.724 | -30.97 | -37.497 | -28.151 | -26.009 | -23.273 | -18.348 | -15.531 | -13.07 | -15.301 | -9.673 |
| Income Before Tax Ratio
| -40.447 | -32.82 | -150.25 | -217.081 | -326.677 | -17.474 | -60.749 | -13.815 | -22.185 | -35.441 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.022 | 0.001 | -0.869 | 0.592 | 0.95 | 1.208 | 0.032 | 0.025 | 0.018 | 0.016 | 0.043 | 0.063 | -0.01 | 0.342 | 1.04 | 0.106 | 0 | 0.32 |
| Net Income
| -31.207 | -28.062 | -39.398 | -32.72 | -33.291 | -31.264 | -31.682 | -30.749 | -30.988 | -37.513 | -28.194 | -26.009 | -23.273 | -18.348 | -15.531 | -13.07 | -15.301 | -9.673 |
| Net Income Ratio
| -40.476 | -32.821 | -147.007 | -221.081 | -336.273 | -18.177 | -60.81 | -13.826 | -22.198 | -35.457 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.38 | -0.45 | -0.66 | -0.55 | -0.56 | -0.53 | -0.54 | -0.53 | -0.54 | -0.66 | -0.52 | -0.48 | -0.43 | -0.33 | -0.37 | -0.31 | -0.37 | -0.23 |
| EPS Diluted
| -0.38 | -0.45 | -0.66 | -0.55 | -0.56 | -0.53 | -0.54 | -0.53 | -0.54 | -0.66 | -0.52 | -0.48 | -0.43 | -0.33 | -0.37 | -0.31 | -0.37 | -0.23 |
| EBITDA
| -32.075 | -28.083 | -27.065 | -28.128 | -24.751 | -29.652 | -28.494 | -27.654 | -29.048 | -36.099 | -27.601 | -24.72 | -22.096 | -17.316 | -14.685 | -12.615 | -10.297 | -9.473 |
| EBITDA Ratio
| -41.602 | -32.846 | -100.989 | -190.054 | -250.01 | -17.24 | -54.691 | -12.434 | -20.808 | -34.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |